USANA prelim FY2025 sales ~$925M (beat guidance); FY2026 guidance $925M-$1B

USANA HEALTH SCIENCES INC

Preliminary FY2025 net sales of ~$925M, above prior guidance of ~$920M.
FY2026 net sales guidance of $925M-$1.0B; core USANA nutritional seen at $720-765M (down from ~$777M).
Hiya segment guided $140-155M (up from ~$132M); Rise Wellness $65-80M (up from ~$16M).
FY2026 is a 52-week year (one week less than FY2025), impacting core business comparison.
Rise Wellness margins expected at breakeven in FY2026 due to growth investments; working capital rising at both Hiya and Rise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.